Antidiabetic therapies affect risk of pancreatic cancer.
Level 4 - case-series / case-control
Hospital-based case-control study
PubMed 19375425 · doi:10.1053/j.gastro.2009.04.013
What was done
A hospital-based case-control study at M. D. Anderson Cancer Center (2004–2008) evaluated 973 patients with pancreatic adenocarcinoma (259 diabetic) and 863 controls (109 diabetic). Diabetes history, risk factors, and antidiabetic medication use (metformin, insulin, insulin secretagogues, and other agents) were collected via personal interview. Risk among diabetic patients was estimated using unconditional logistic regression adjusted for potential confounders.
What was found
Diabetic patients who took metformin had a significantly lower risk of pancreatic cancer compared to non-users (odds ratio 0.38; 95% CI, 0.22–0.69; P = .001). This association remained significant when restricting the analysis to individuals with a diabetes duration >2 years or those who never used insulin. Diabetic patients taking insulin or insulin secretagogues had a significantly higher risk of pancreatic cancer compared with non-users of these agents, though specific odds ratios and confidence intervals were not reported in the abstract.
Why it matters
This study provides observational evidence that specific antidiabetic therapies may differentially modify pancreatic cancer risk, suggesting a potential protective role for metformin.
Limits
The hospital-based case-control design introduces potential selection bias, recall bias from self-reported interview data, and confounding by diabetes severity or indication. Reverse causality is a key concern given that early-stage pancreatic cancer frequently induces secondary diabetes. Numerical estimates and confidence intervals for insulin and secretagogue use were not reported in the abstract.
Cited by
- supports Type 2 diabetics taking metformin have a 62% reduced risk of developing pancreatic cancer.